Chronic diseases such as obesity, Diabetes, Inflammatory Bowel Disease, allergies, and others are becoming more frequent according to statistics.
Nevertheless, health programs based on traditional strategies are not having the expected results. On the other hand, scientific findings have linked
the gut microbiota role with metabolism, immune and hormonal response, as well as the brain-intestine axis finding. All these results had not been
used in clinical practice. During last years, there have been collected scientific results from Centro de Investigación y Asistencia en Tecnología y Diseño
del Estado de Jalisco A. C. and Grupo MaBiosis to apply this findings to create a system to evaluate traditional parameters and include gut microbiota
parameters to generate a more accurate diagnosis; decide the best treatment, based on this diagnosis, and re-evaluate treatment to prove this treatment
is the best for each patient. This system promotes the use of all these avant-garde technology in patients under health protocols with a higher response
rate, then it has been developed to enrich clinical practice for health specialist and is able to be adapted to any specialty area in health sciences. It is
considered crucial, to use technology a scientific finding to combat current problems.

In accord to [1], overweight is a public problem health in all life
stages. About 1.9 million of adults aged 18 years and older were
overweight, and about 650 million were obese. About 41 million
children younger than the age of 5 were overweight too in 2016.
World Health Organization, Health programs continuous using the
same strategies based on exercise and negative calorie balance
without results. On the other hand, inflammatory and immunology
diseases are more frequent. In accord to the Centers for Disease
Control & Prevention reports, in United States, the prevalence of food
allergy between 1997 and 2011 had increased in children about 50
percent [2]. (Food Allergy Research & Education) statistics reports
show that health program strategies are failed, and it is necessary
to look for new strategies, based on science to combat current
problems. Different authors have determined that gut microbiota
(GM), which is a complex ecosystem that includes a collection of
organisms that live in the intestine, could play an important role
in metabolism, immune response and endocrinology. Research
performed together in Grupo MaBiosis S.A. de C.V. and the center
of research Centro de Investigación y Asistencia en Tecnología y
Diseño del Estado de Jalisco, A.C. (CIATEJ) during last seven years,
have use this information to create a Diagnostic and Treatment
System based on the GM balance that can be used as a tool for any
patient to improve treatment response. Different research projects
were focused on to analyze microbial population in different life
stage, different pathologic conditions such as Inflammatory Bowel
Disease, obesity and overweight, and all this data could determine
patters (microorganisms and metabolites) that were linked to
patient’s clinical information (clinical chemistry, anthropometry,
dietetic, clinical evidence, signs and symptoms).

[3] determine that different strains of Bifidobacterium could
stimulate systemic and intestinal immunity. [3,4] discover there is
a significant impact on initial colonization, in accord to the birth
canal, where infants born vaginally had an increased abundance
of Bifidobacterium than those born by cesarean section. [4] was
founded the field of microbial endocrinology, defined as “the
study of the ability of microorganisms to produce and recognize
neurochemicals that originate either within the microorganisms
themselves or within the host they inhabit”. [5] is where the role of
short chain fatty acids (SCFA) and other metabolites get crucial for
host metabolism. Some authors have reported the role of specific
SCFA such as propionic acid in hepatic gluconeogenesis inhibition,
increasing lipolysis; butyric acid as the principal substrate of
colonocytes, promoting tight junctions’ formation and improve
membrane permeability; acetic acid that promotes an acid pH to
inhibit pathogens proliferation in gut, and other beneficial effects
[6,7].

Other studies, [8] determine than GM diversity could be a
determining factor due to profiles were reduced in patients with
primary sclerosing cholangitis, IBD compared to healthy controls
[8]. Nevertheless, until now, there are lots of results where GM
plays a crucial paper in health and disease; all these results had
not been applied in clinical practice, so health specialists continue
using traditional strategies that learned in university.

The system presented in this publication is performed in three
stages:

A. Bioanalysis: where different parameters from the
patient are evaluated: those that are well recognized and widely
used (clinical chemistry, anthropometric, dietetic, etcetera) and
an innovative parameter: GM analysis that can be determine
by microbiology and other techniques (sequencing, PCR) the
presence or absence of microorganism consider as biomarkers
or stablish GM profiles. The conjunction of all these parameters
will allow a better diagnosis in an integral way. However, other
types of measurements can be added, such as specialized cabinet
studies (imaging, radiology, more specific determinations such as
hormonal), among others.

B. Biological restauration: in accord to results interpretation
from Bioanalysis, the health specialist will decide the best treatment
for every patient. It could include different strategies

a) Dietary changes: using a specific diet (FODMAP free, Ceto,
vegan, etcetera. The best dietetic plan for each patient.

b) The use of probiotics, prebiotics o symbiotics: GM analysis
provides enough information to determine a product that could
improve patient´s health in accord their need. Although there is a
disadvantage: just a few products have clinical trial.

c) Pharmacotherapy: is established according to the
diagnosis of the patient for the treatment of a present pathology,
symptomatology or a metabolic imbalance.

d) Intestinal conditioning: is established according to the
intestinal microbiota profile, in the case of presenting significant
symptoms (such as inflammation, distension, or lack of response
to a specific treatment) due to the presence of yeast and/or a
pathogenic agent, is present or not an infection. This therapy is
followed by a recolonization therapy, in order to recolonize in a
targeted and personalized way.

e) Combination of the previous ones.

C. Re-evaluation: It is important to partially evaluate the
results obtained in the second stage of this system in order to
monitor this same treatment or adjust the course of treatment. And if necessary, conduct more specialized studies. Following
scientific evidence, patients from different health specialists have
followed this system presented with higher response rates to their
treatments. Since last year, this system has been used daily by
about 20 health specialists in Mexico (nutritionists, infectologists,
pediatricians, naturopath doctors, internists, endocrinologists,
gastroenterologists) in their clinical practice. Last year, there
were required about 500GM analyses for patient follow up with
higher response rate to their treatment. Using this system, both,
health specialist and patient discover some patients had specific
intolerance to some food ingredients, or they discover the diagnosis
of inflammatory bowel disease was not correct for some of them,
some others could finally lose weight, some others discover they
began to gain weight after an antibiotic treatment.

Financial Support

Sponsors

Latest e-Books

Latest Video

About Crimson

We at Crimson Publishing are a group of people with a combined passion for science and research, who wants to bring to the world a unified platform where all scientific know-how is available
read more...